Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KZIANASDAQ:NEPTNASDAQ:SONNNASDAQ:THAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKZIAKazia Therapeutics$9.30-5.0%$4.12$2.86▼$79.00$9.37M2.48380,127 shs374,175 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsSONNSonnet BioTherapeutics$1.15-2.5%$1.26$1.08▼$14.80$3.64M0.94384,892 shs22,349 shsTHARTharimmune$1.29-5.8%$1.37$0.95▼$6.39$3.43M1.04374,440 shs40,496 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKZIAKazia Therapeutics-5.01%+64.60%+155.49%+86.90%-25.57%NEPTNeptune Wellness Solutions0.00%0.00%0.00%0.00%0.00%SONNSonnet BioTherapeutics-2.54%-8.00%-11.20%-15.74%-35.75%THARTharimmune-5.84%-14.56%-7.86%-11.03%-58.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKZIAKazia Therapeutics3.5766 of 5 stars3.55.00.00.02.50.00.0NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/ASONNSonnet BioTherapeutics2.8042 of 5 stars3.55.00.00.02.80.00.6THARTharimmune3.0992 of 5 stars3.85.00.00.02.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKZIAKazia Therapeutics 3.00Buy$57.50518.28% UpsideNEPTNeptune Wellness Solutions 0.00N/AN/AN/ASONNSonnet BioTherapeutics 3.00Buy$20.001,639.13% UpsideTHARTharimmune 3.50Strong Buy$17.001,217.83% UpsideCurrent Analyst Ratings BreakdownLatest NEPT, THAR, KZIA, and SONN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025KZIAKazia TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.004/7/2025SONNSonnet BioTherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/28/2025SONNSonnet BioTherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKZIAKazia Therapeutics$2.31M4.06N/AN/A($1.97) per share-4.72NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00SONNSonnet BioTherapeutics$1M3.64N/AN/A$1.32 per share0.87THARTharimmuneN/AN/AN/AN/A$195.44 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKZIAKazia Therapeutics-$17.56MN/A0.00∞N/AN/AN/AN/AN/ANEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%N/ASONNSonnet BioTherapeutics-$7.44MN/A0.00∞N/AN/A-408.93%-174.13%8/13/2025 (Estimated)THARTharimmune-$9.32M-$7.88N/A∞N/AN/A-167.63%-130.18%N/ALatest NEPT, THAR, KZIA, and SONN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025SONNSonnet BioTherapeutics-$0.92-$0.89+$0.03-$0.89N/AN/A5/12/2025Q1 2025THARTharimmune-$0.84-$0.99-$0.15-$0.99N/AN/A3/25/2025Q4 2024THARTharimmuneN/A-$2.02N/A-$2.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKZIAKazia TherapeuticsN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ASONNSonnet BioTherapeuticsN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKZIAKazia TherapeuticsN/A0.240.24NEPTNeptune Wellness SolutionsN/A0.230.10SONNSonnet BioTherapeuticsN/A2.152.15THARTharimmuneN/A2.352.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKZIAKazia Therapeutics30.89%NEPTNeptune Wellness Solutions14.44%SONNSonnet BioTherapeutics9.45%THARTharimmune1.16%Insider OwnershipCompanyInsider OwnershipKZIAKazia Therapeutics1.00%NEPTNeptune Wellness Solutions5.10%SONNSonnet BioTherapeutics2.00%THARTharimmune10.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKZIAKazia Therapeutics121.01 million4.99 millionOptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableSONNSonnet BioTherapeutics103.17 million3.01 millionNot OptionableTHARTharimmune22.66 million1.89 millionNot OptionableNEPT, THAR, KZIA, and SONN HeadlinesRecent News About These CompaniesTharimmune announces executive changes and new agreementsJune 13 at 3:42 PM | investing.comTharimmune advances opioid prophylaxis drug TH104May 7, 2025 | investing.comTharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA FeedbackMay 6, 2025 | accessnewswire.comTharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL ConferencesMay 1, 2025 | accessnewswire.comTharimmune Appoints Clay Kahler and Gary Stetz to its Board of DirectorsApril 30, 2025 | accessnewswire.comTharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA FeedbackApril 28, 2025 | sacbee.comTharimmune announces board retirements ahead of annual meetingApril 26, 2025 | investing.comTharimmune Inc.: Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of DirectorsApril 15, 2025 | finanznachrichten.deTharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of DirectorsApril 15, 2025 | accessnewswire.comTharimmune reports data on new biparatopic biologicsApril 9, 2025 | bioworld.comTharimmune announces preclinical data from expanded pipeline with HS1940April 9, 2025 | markets.businessinsider.comTharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) TechnologyApril 7, 2025 | accessnewswire.comTharimmune receives Nasdaq non-compliance noticeApril 6, 2025 | investing.comTharimmune announces FDA feedback on NDA path for TH104April 1, 2025 | markets.businessinsider.comTharimmune announces FDA feedback on TH104 NDA pathApril 1, 2025 | markets.businessinsider.comTharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid ExposureMarch 31, 2025 | accessnewswire.comTharimmune announce preclinical TH023 resultsMarch 25, 2025 | markets.businessinsider.comTharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alphaMarch 24, 2025 | accessnewswire.comTharimmune leverages Epiclick platform to expand pipelineMarch 6, 2025 | bioworld.comTharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick TechnologyMarch 4, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNEPT, THAR, KZIA, and SONN Company DescriptionsKazia Therapeutics NASDAQ:KZIA$9.30 -0.49 (-5.01%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.40 +0.09 (+1.02%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Neptune Wellness Solutions NASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. Sonnet BioTherapeutics NASDAQ:SONN$1.15 -0.03 (-2.54%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$1.15 0.00 (0.00%) As of 06/13/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.Tharimmune NASDAQ:THAR$1.29 -0.08 (-5.84%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$1.31 +0.02 (+1.55%) As of 06/13/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
